ManufacturingWith a $70 million expansion in Massachusetts, AbbVie plans...
Manufacturing

With a $70 million expansion in Massachusetts, AbbVie plans the next phase of its US investment adventure

Editotial Team
By Editotial Team

-

1082
0

No content provided.

e8ca33a26f7037921e92de08cb2a519d8f9a37c9966383abf07edbf18b55cb25?s=150&d=mp&r=g
+ posts
Previous article
Rocket abandons its attempt to obtain FDA approval for bone marrow gene therapy
Next article
Aerska Launches with $21 Million to Develop RNAi Medicines for Neurological Diseases
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team

Latest news

Insights

The Science Behind Bispecific Antibodies and Their Therapeutic Potential

Executive Summary Bispecific antibodies are an increasingly important class of engineered biologic medicines designed to recognize two distinct molecular targets...
Insights

Top 10 Emerging Technologies in Microbial Biotechnology

Executive Summary Microbial biotechnology is advancing as new technologies expand the ability to engineer, understand, and utilize microorganisms for industrial,...
Commercial

Delix Therapeutics Raises $100 Million to Advance Zalsupindole for Depression

Delix Therapeutics has raised $100 million through an oversubscribed Series C financing round to advance its investigational psychedelic-derived medicine,...

Must read

Commercial

Commercial Excellence Summit Brings Together Leading Minds to Solve Critical Commercial Problems

This week is set to be a pivotal one...
Commercial

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you